MML Investors Services LLC Decreases Stock Holdings in Sanofi (NASDAQ:SNY)

MML Investors Services LLC cut its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 7.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 230,536 shares of the company's stock after selling 17,716 shares during the quarter. MML Investors Services LLC's holdings in Sanofi were worth $13,286,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SNY. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi during the 3rd quarter worth $29,000. POM Investment Strategies LLC purchased a new stake in shares of Sanofi in the second quarter valued at about $25,000. Concord Wealth Partners increased its stake in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after purchasing an additional 363 shares in the last quarter. Arrow Financial Corp acquired a new position in shares of Sanofi during the 2nd quarter worth approximately $35,000. Finally, Fortitude Family Office LLC raised its position in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock worth $43,000 after purchasing an additional 659 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company's stock.

Sanofi Trading Down 0.2 %

SNY stock traded down $0.09 during midday trading on Wednesday, hitting $47.99. The stock had a trading volume of 1,866,252 shares, compared to its average volume of 2,058,165. The company's 50-day moving average price is $51.53 and its 200 day moving average price is $52.12. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market cap of $121.79 billion, a PE ratio of 24.53, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the previous year, the business earned $2.55 earnings per share. The business's revenue for the quarter was up 12.3% on a year-over-year basis. On average, equities research analysts predict that Sanofi will post 4.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Citigroup upgraded Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sanofi has a consensus rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.